BDBM108116 US8598206, Table 6, 3

SMILES COC(=O)c1cccc(CS(=O)(=O)N[C@H](CCCc2ccccc2)C(=O)N[C@@H](CCC2CCNCC2)C(=O)NCc2ccc(cc2)C(N)=N)c1

InChI Key InChIKey=JPGNXUNXIAMWMQ-JHOUSYSJSA-N

Data  10 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 108116   

TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  2.70nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  9.40nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  500nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVitamin K-dependent protein C(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  570nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTranscription initiation factor IIA subunit 1(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  920nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  3.90E+3nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement C1s subcomponent(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  4.80E+3nMAssay Description: Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  5.90E+3nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XII(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi: >1.00E+4nMAssay Description:Inhibition of human alpha-FXIIa was determined by the method described in [0092]-[0098] using activated human alpha-Factor XII (activated Hageman Fac...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement C1r subcomponent(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem...More data for this Ligand-Target Pair
In DepthDetails US Patent